INDIANAPOLIS, May 23, 2007 -- Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR® (gemcitabine HCl for injection), ALIMTA® (pemetrexed for injection), and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies.
"This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding the right drug, at the right dose, for the right patient at the right time will be demonstrated at ASCO this year."
Key Lilly Abstracts for ASCO 2007:
- ALIMTA® (pemetrexed for injection)
Phase III Study of ALIMTA in First-line NSCLC
Abstract # 7517: June 2, 2007; 3:00 p.m.
Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the treatment of stage IIIB/IV NSCLC
- Large Meta-analysis of Diverse Patients with NSCLC
Publication: 2007 ASCO Meeting Program
Effect of race on the safety and efficacy of pemetrexed therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC)
- Phase II Evaluation of ALIMTA Using Accelerated Vitamin Supplementation in Small Cell Lung Cancer
Abstract # 7726: June 3, 2007: 8:00 a.m.
The impact of shortened vitamin supplementation lead-in time before pemetrexed in patients with relapsed small cell lung cancer (SCLC)
- Early-phase Trial of ALIMTA +/- Steroids in Head & Neck Cancer
Abstract # 6055: June 4, 2007: 1:00 p.m.
A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer
- GEMZAR® (gemcitabine HCl for injection)
Phase III Study of GEMZAR Combination in Neoadjuvant (Pre-Surgical) Breast Cancer
Abstract # 595: June 2, 2007; 2:00 p.m.
Neoadjuvant chemotherapy with a dose-dense sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine +/- trastuzumab in stage II and III breast cancer
Phase II Data of Targeted, Oral Agent enzastaurin in Second- & Third-line NSCLC
Abstract # 7543: June 2, 2007; 8:00 a.m.
A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
For more information on Lilly Oncology agents, including full prescribing information, please see the attached fact sheet, or, if you are receiving this electronically, you can view full prescribing information on www.lillyoncology.com.